The Centers for Disease Control and Prevention (CDC) has altered its longstanding recommendation for hepatitis B vaccination, shifting from universal immunization of newborns to a more selective approach based on parental decision-making and, in some cases, testing. The change, approved December 16, 2025, marks a significant departure from the policy in place since 1991.
Previously, the CDC advised that all infants receive a dose of the hepatitis B vaccine within 24 hours of birth, followed by subsequent doses at one to two months and between six and 18 months. This strategy led to a 99% reduction in acute hepatitis B infections among children and teenagers between 1990 and 2019, according to data cited in reporting on the change.
Under the new guidelines, the CDC now recommends that only infants born to mothers known to have hepatitis B, or whose infection status is unknown, receive the birth dose. For all other newborns, the decision to vaccinate is left to parents in consultation with their healthcare providers. The CDC describes this as a “shared clinical decision-making” model.
The revised recommendations also impact the timing of subsequent doses. The CDC suggests that infants not receiving the birth dose should not receive their first dose until they are at least two months old. The agency now recommends considering antibody testing between doses to determine the require for additional vaccinations, a practice that experts say has not been previously studied.
Hepatitis B is a highly contagious virus transmitted through contact with infected body fluids, including blood, semen, and vaginal secretions. While often asymptomatic in initial stages, chronic infection can lead to severe liver damage, liver failure, liver cancer, and death. Infants infected at birth or during the first year of life have a 90% chance of developing a chronic infection, a rate significantly higher than that for older children.
The CDC’s shift in policy has drawn criticism from some medical professionals who argue that it will introduce confusion and potentially leave infants vulnerable. The virus can survive outside the body for up to seven days, increasing the risk of transmission through everyday items like toothbrushes and razors, or through accidental contact with blood during play.
The hepatitis B vaccine has been administered over a billion times worldwide since 1982, with a strong safety record. Common side effects are typically mild, including headache, fever, and soreness at the injection site. The rate of reported acute hepatitis B infections declined 88.5% since the vaccine was first recommended in 1982, falling from 9.6 cases per 100,000 population to 1.1 cases per 100,000 population in 2015.
According to the CDC, the change reflects a desire to empower parents with more control over their children’s healthcare decisions. However, the agency has not yet released detailed guidance on how healthcare providers should facilitate these shared decision-making conversations, leaving some uncertainty about the practical implementation of the new recommendations.
